Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Huntington Disease
Isis Reports Financial Results and Highlights for Third Quarter of 2007
November 22nd, 2007
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced its financial results and highlights for the third quarter ended September 30, 2007. Isis had $10.1 million of income from operations in the third quarter of 2007 and a loss from operations for the nine months ended September 30, 2007 of $30.5 million compared to a loss from operations of $18.3 million and $51.4 million for the three and nine months ended September 30, 2006, according to GAAP. Isis' strong financial results demonstrate the value Isis is recognizing from its dominant position in antisense technology. As previously announced, based on its financial results for the first nine months of 2007 and its projection for the fourth...
Source: Genetics & Environmental Business Week (2007-11-22)
|
